Study Evaluating the Benefit of Two Immunosuppressive Strategies on Renal Function

Summary

Prospective, multicenter, randomized and open label study evaluating the benefit on renal function at 12 months post-transplantation, with an immunosuppression without calcineurin inhibitor at 3 months and combining mycophenolate sodium-Everolimus versus an immunosuppression combining Everolimus-Tacrolimus, in de novo renal transplant patients.

Timeline

Start

2014-12-11

Primary completion

2019-05-31

Completion

2020-07-03

Drugs

Indications